EWTX - Edgewise Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.00
DETAILS
HIGH:
$52.00
LOW:
$25.00
MEDIAN:
$45.50
CONSENSUS:
$42.00
UPSIDE:
28.44%
About Edgewise Therapeutics, Inc. (https://www.edgewisetx.com)
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Kevin Koch | President, Chief Executive Officer & Director | 1960 | $1,146,300 USD |
| Behrad Derakhshan | Chief Operating Officer | 1980 | $803,100 USD |
| Joanne Donovan | Chief Medical Officer | 1957 | $788,323 USD |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director | 1970 | $737,866 USD |
| Michael Nofi | Chief Financial Officer | 1971 | $97,700 USD |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman | 1960 | $80,000 USD |
| Badreddin Edris | Co-Founder & Independent Director | 1987 | $55,000 USD |
| John R. Moore | General Counsel | 1964 | – |
| Robert Blaustein | Chief Development Officer | 1961 | – |